Can thrombus age guide thrombolytic therapy?

Christopher Czaplicki, Hassan Albadawi, Sasan Partovi, Ripal T. Gandhi, Keith Quencer, Amy R. Deipolyi, Rahmi Oklu

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

Venous thrombosis (VT) is a common yet complex clinical condition that has shown minimal alteration in clinical management for decades. It is well known that thrombus evolves structurally over time, with complex changes resulting from the interplay between coagulation factors, cytokines, leukocytes and a myriad of other factors. Our current treatment options are most effective in the acute thrombus, which is composed predominantly of a loose mesh of fibrin and red blood cells (RBCs), making current anticoagulation therapies and thrombolytics quite effective in treatment. Later stages of thrombus are more cellular containing leukocytes, and develop a fibrotic collagenous framework that is more resistant to our current treatments. Understanding the biology of an evolving thrombus will allow us to tailor our treatment and optimize outcomes, as well as focus on novel therapies for the treatment of chronic thrombus. Given the morbidity and mortality of both post thrombotic syndrome (PTS) in patients with deep VT, as well as chronic thromboembolic pulmonary hypertension (CTEPH) in patients with pulmonary embolism (PE), new and innovative therapies must continue to be explored to help prevent these potentially devastating conditions.

Original languageEnglish (US)
Pages (from-to)S186-S196
JournalCardiovascular Diagnosis and Therapy
Volume7
DOIs
StatePublished - Dec 1 2017

Fingerprint

Thrombolytic Therapy
Thrombosis
Venous Thrombosis
Leukocytes
Therapeutics
Investigational Therapies
Blood Coagulation Factors
Fibrin
Pulmonary Embolism
Pulmonary Hypertension
Erythrocytes
Cytokines
Morbidity
Mortality

Keywords

  • Anticoagulants
  • Pulmonary embolism (PE)
  • Venous thromboembolism
  • Venous thrombosis (VT)

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Czaplicki, C., Albadawi, H., Partovi, S., Gandhi, R. T., Quencer, K., Deipolyi, A. R., & Oklu, R. (2017). Can thrombus age guide thrombolytic therapy? Cardiovascular Diagnosis and Therapy, 7, S186-S196. https://doi.org/10.21037/cdt.2017.11.05

Can thrombus age guide thrombolytic therapy? / Czaplicki, Christopher; Albadawi, Hassan; Partovi, Sasan; Gandhi, Ripal T.; Quencer, Keith; Deipolyi, Amy R.; Oklu, Rahmi.

In: Cardiovascular Diagnosis and Therapy, Vol. 7, 01.12.2017, p. S186-S196.

Research output: Contribution to journalReview article

Czaplicki, C, Albadawi, H, Partovi, S, Gandhi, RT, Quencer, K, Deipolyi, AR & Oklu, R 2017, 'Can thrombus age guide thrombolytic therapy?', Cardiovascular Diagnosis and Therapy, vol. 7, pp. S186-S196. https://doi.org/10.21037/cdt.2017.11.05
Czaplicki C, Albadawi H, Partovi S, Gandhi RT, Quencer K, Deipolyi AR et al. Can thrombus age guide thrombolytic therapy? Cardiovascular Diagnosis and Therapy. 2017 Dec 1;7:S186-S196. https://doi.org/10.21037/cdt.2017.11.05
Czaplicki, Christopher ; Albadawi, Hassan ; Partovi, Sasan ; Gandhi, Ripal T. ; Quencer, Keith ; Deipolyi, Amy R. ; Oklu, Rahmi. / Can thrombus age guide thrombolytic therapy?. In: Cardiovascular Diagnosis and Therapy. 2017 ; Vol. 7. pp. S186-S196.
@article{aab075f73d764e76bd1ca7b54197710d,
title = "Can thrombus age guide thrombolytic therapy?",
abstract = "Venous thrombosis (VT) is a common yet complex clinical condition that has shown minimal alteration in clinical management for decades. It is well known that thrombus evolves structurally over time, with complex changes resulting from the interplay between coagulation factors, cytokines, leukocytes and a myriad of other factors. Our current treatment options are most effective in the acute thrombus, which is composed predominantly of a loose mesh of fibrin and red blood cells (RBCs), making current anticoagulation therapies and thrombolytics quite effective in treatment. Later stages of thrombus are more cellular containing leukocytes, and develop a fibrotic collagenous framework that is more resistant to our current treatments. Understanding the biology of an evolving thrombus will allow us to tailor our treatment and optimize outcomes, as well as focus on novel therapies for the treatment of chronic thrombus. Given the morbidity and mortality of both post thrombotic syndrome (PTS) in patients with deep VT, as well as chronic thromboembolic pulmonary hypertension (CTEPH) in patients with pulmonary embolism (PE), new and innovative therapies must continue to be explored to help prevent these potentially devastating conditions.",
keywords = "Anticoagulants, Pulmonary embolism (PE), Venous thromboembolism, Venous thrombosis (VT)",
author = "Christopher Czaplicki and Hassan Albadawi and Sasan Partovi and Gandhi, {Ripal T.} and Keith Quencer and Deipolyi, {Amy R.} and Rahmi Oklu",
year = "2017",
month = "12",
day = "1",
doi = "10.21037/cdt.2017.11.05",
language = "English (US)",
volume = "7",
pages = "S186--S196",
journal = "Cardiovascular Diagnosis and Therapy",
issn = "2223-3652",
publisher = "AME Publishing Company",

}

TY - JOUR

T1 - Can thrombus age guide thrombolytic therapy?

AU - Czaplicki, Christopher

AU - Albadawi, Hassan

AU - Partovi, Sasan

AU - Gandhi, Ripal T.

AU - Quencer, Keith

AU - Deipolyi, Amy R.

AU - Oklu, Rahmi

PY - 2017/12/1

Y1 - 2017/12/1

N2 - Venous thrombosis (VT) is a common yet complex clinical condition that has shown minimal alteration in clinical management for decades. It is well known that thrombus evolves structurally over time, with complex changes resulting from the interplay between coagulation factors, cytokines, leukocytes and a myriad of other factors. Our current treatment options are most effective in the acute thrombus, which is composed predominantly of a loose mesh of fibrin and red blood cells (RBCs), making current anticoagulation therapies and thrombolytics quite effective in treatment. Later stages of thrombus are more cellular containing leukocytes, and develop a fibrotic collagenous framework that is more resistant to our current treatments. Understanding the biology of an evolving thrombus will allow us to tailor our treatment and optimize outcomes, as well as focus on novel therapies for the treatment of chronic thrombus. Given the morbidity and mortality of both post thrombotic syndrome (PTS) in patients with deep VT, as well as chronic thromboembolic pulmonary hypertension (CTEPH) in patients with pulmonary embolism (PE), new and innovative therapies must continue to be explored to help prevent these potentially devastating conditions.

AB - Venous thrombosis (VT) is a common yet complex clinical condition that has shown minimal alteration in clinical management for decades. It is well known that thrombus evolves structurally over time, with complex changes resulting from the interplay between coagulation factors, cytokines, leukocytes and a myriad of other factors. Our current treatment options are most effective in the acute thrombus, which is composed predominantly of a loose mesh of fibrin and red blood cells (RBCs), making current anticoagulation therapies and thrombolytics quite effective in treatment. Later stages of thrombus are more cellular containing leukocytes, and develop a fibrotic collagenous framework that is more resistant to our current treatments. Understanding the biology of an evolving thrombus will allow us to tailor our treatment and optimize outcomes, as well as focus on novel therapies for the treatment of chronic thrombus. Given the morbidity and mortality of both post thrombotic syndrome (PTS) in patients with deep VT, as well as chronic thromboembolic pulmonary hypertension (CTEPH) in patients with pulmonary embolism (PE), new and innovative therapies must continue to be explored to help prevent these potentially devastating conditions.

KW - Anticoagulants

KW - Pulmonary embolism (PE)

KW - Venous thromboembolism

KW - Venous thrombosis (VT)

UR - http://www.scopus.com/inward/record.url?scp=85038623495&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85038623495&partnerID=8YFLogxK

U2 - 10.21037/cdt.2017.11.05

DO - 10.21037/cdt.2017.11.05

M3 - Review article

AN - SCOPUS:85038623495

VL - 7

SP - S186-S196

JO - Cardiovascular Diagnosis and Therapy

JF - Cardiovascular Diagnosis and Therapy

SN - 2223-3652

ER -